Screening for prostate cancer

BMJ (Online)

Volumn 341, Issue 7773, 2010, Pages 563-

  Andriole Jr , Gerald L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER LOCALIZATION; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; DIET; EDITORIAL; ETHNICITY; HEALTH CARE COST; HUMAN; LIFESTYLE MODIFICATION; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; TUMOR GROWTH; TUMOR VOLUME;

HUMANS; MALE; META-ANALYSIS AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 77956802891     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c4538     Document Type: Editorial

References (12)

1. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al; for the PLCO Project Team. Mortality results from a prostate-cancer screening trial. N Engl J Med 2009;360:1310-9. [CrossRef] [Medline]
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8. [CrossRef] [Medline]
3. Djulbegovic M, Beyth RB, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543. [Abstract/FREE Full text]
4. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83. [Abstract/FREE Full text]
5. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90. [Abstract/FREE Full text] (Pubitemid 34814727)
6. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. J Clin Oncol 2009;27:1502-16. [Abstract/FREE Full text]
7. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-2002. [CrossRef] [Medline]
8. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31. [Abstract/FREE Full text]
9. Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010;341:c4521. [Abstract/FREE Full text]
10. Jansen FH, van Schaik RHN, Kurstjens J, Horninger W, Klocker H, Bektic J, et al. Prostate-specific antigen (PSA) isoform p2psa in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921-7. [CrossRef] [Web of Science]
11. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-9. [CrossRef] [Medline] [Web of Science] (Pubitemid 47037039)
12. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009;101:1325-9. [Abstract/FREE Full text]